To better stratify the subgroup of patients who will most likely benefit from these ICIs, radiomic biomarkers are being developed so that they can be used as a surrogate to PD-L1 expression as well as to predict PFS and OS of NSCLC patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.